Antibiotics do not lower Avastin infection risk

Article

The incidence of endophthalmitis is independent of whether prophylactic antibiotics are administered in conjunction with Avastin (bevacizumab) injections, according to results of a study published in the February 2008 issue of Spektrum der Augenheilkunde.

Prophylactic antibiotics do not lower the incidence of endophthalmitis in patients receiving Avastin (bevacizumab) injections, according to results of a study published in the February 2008 issue of Spektrum der Augenheilkunde.

Carsten H. Meyer, MD of the Augenklinik at Bonn University, Germany and colleagues conducted a retrospective study of two groups of patients receiving 1.25 mg/0.05 ml Avastin after an incubation of 5% povidone-iodine for 60 seconds in the conjunctival fornix. The first set of subjects (Group A; n=984) underwent the injection as an outpatient procedure and received no prophylactic antibiotics after the injection. In the second set (Group B; n=860), patients were admitted to hospital for one day and received three days of topical antibiotics following the injection.

The subjects of Group A had a zero incidence of post-injection endophthalmitis; two patients developed intraocular uveitis, which was treated successfully with topical steroids. In Group B, the two cases of post-injection endophthalmitis that developed after five days were treated with vitrectomy.

The researchers concluded that administration of prophylactic antibiotics was unable to eliminate endophthalmitis in these cases; when considering this factor, it is irrelevant whether the injection of Avastin is administered on an inpatient or outpatient basis.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.